Obizur
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Susoctocog alfa
- Used in
- Blood, clotting and anaemia
- Made by
- Baxalta Innovations GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Baxalta Innovations GmbH |
|---|---|
| Active substance | Susoctocog alfa |
| Used in | Blood, clotting and anaemia |
| Classification | B02 · Blood, clotting and anaemia |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2015-11-11 |
| Last updated by the regulator | 2025-11-21 |
| EMA product number | EMEA/H/C/002792 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).